Alerts will be sent to your verified email
Verify EmailPARMAX
Parmax Pharma
|
Beryl Drugs
|
Unjha Formulations
|
|
---|---|---|---|
Operational Metrics
|
|||
Financials
|
|||
5 yr Average ROE
|
-1624.87 % | 2.54 % | 10.34 % |
5yr average Equity Multiplier
|
46.04 | 2.23 | 1.62 |
5yr Average Asset Turnover Ratio
|
0.95 | 1.08 | 3.51 |
5yr Avg Net Profit Margin
|
-9.48 % | 0.66 % | 1.88 % |
Price to Book
|
0.0 | 1.16 | 3.5 |
P/E
|
0.0 | 49.26 | 114.12 |
5yr Avg Cash Conversion Cycle
|
-161.05 Days | -619.24 Days | 18.8 Days |
Inventory Days
|
73.65 Days | 36.1 Days | 28.57 Days |
Days Receivable
|
40.27 Days | 98.89 Days | 41.04 Days |
Days Payable
|
328.05 Days | 969.29 Days | 53.92 Days |
5yr Average Interest Coverage Ratio
|
1.16 | 1.68 | 17.56 |
5yr Avg ROCE
|
-9.94 % | 5.73 % | 19.44 % |
5yr Avg Operating Profit Margin
|
3.93 % | 7.19 % | 3.19 % |
5 yr average Debt to Equity
|
17.42 | 0.64 | 0.0 |
5yr CAGR Net Profit
|
n/a | 72.78 % | 32.6 % |
5yr Average Return on Assets
|
-6.43 % | 1.31 % | 6.62 % |
Shareholdings
|
|||
Promoter Holding
|
30.8 % | 26.38 % | 36.92 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.0 | 1.46 % | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
Parmax Pharma
|
Beryl Drugs
|
Unjha Formulations
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|